Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $809.32 million. The enterprise value is $462.48 million.
Important Dates
The next estimated earnings date is Monday, May 5, 2025, after market close.
Earnings Date | May 5, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RCKT has 106.63 million shares outstanding. The number of shares has increased by 12.85% in one year.
Current Share Class | 106.63M |
Shares Outstanding | 106.63M |
Shares Change (YoY) | +12.85% |
Shares Change (QoQ) | +3.58% |
Owned by Insiders (%) | 2.43% |
Owned by Institutions (%) | 89.53% |
Float | 86.24M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 1.76 |
PB Ratio | 1.74 |
P/TBV Ratio | 2.03 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.30, with a Debt / Equity ratio of 0.06.
Current Ratio | 9.30 |
Quick Ratio | 9.15 |
Debt / Equity | 0.06 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -144.86 |
Financial Efficiency
Return on equity (ROE) is -54.14% and return on invested capital (ROIC) is -33.94%.
Return on Equity (ROE) | -54.14% |
Return on Assets (ROA) | -31.22% |
Return on Invested Capital (ROIC) | -33.94% |
Return on Capital Employed (ROCE) | -56.10% |
Revenue Per Employee | n/a |
Profits Per Employee | -$865,371 |
Employee Count | 299 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.15% in the last 52 weeks. The beta is 1.03, so RCKT's price volatility has been similar to the market average.
Beta (5Y) | 1.03 |
52-Week Price Change | -72.15% |
50-Day Moving Average | 9.62 |
200-Day Moving Average | 15.74 |
Relative Strength Index (RSI) | 34.04 |
Average Volume (20 Days) | 1,578,162 |
Short Selling Information
The latest short interest is 11.24 million, so 10.54% of the outstanding shares have been sold short.
Short Interest | 11.24M |
Short Previous Month | 10.52M |
Short % of Shares Out | 10.54% |
Short % of Float | 13.03% |
Short Ratio (days to cover) | 8.06 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -273.21M |
Pretax Income | -253.26M |
Net Income | -258.75M |
EBITDA | -263.83M |
EBIT | -273.21M |
Earnings Per Share (EPS) | -$2.73 |
Full Income Statement Balance Sheet
The company has $372.34 million in cash and $25.50 million in debt, giving a net cash position of $346.84 million or $3.25 per share.
Cash & Cash Equivalents | 372.34M |
Total Debt | 25.50M |
Net Cash | 346.84M |
Net Cash Per Share | $3.25 |
Equity (Book Value) | 463.23M |
Book Value Per Share | 4.35 |
Working Capital | 337.50M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$209.72 million and capital expenditures -$5.86 million, giving a free cash flow of -$215.59 million.
Operating Cash Flow | -209.72M |
Capital Expenditures | -5.86M |
Free Cash Flow | -215.59M |
FCF Per Share | -$2.02 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |